Daniel M. Bradbury

Background

Mr. Daniel M. Bradbury, also known as Dan, serves as a Vice President of BIOCOM, Inc. Mr. Bradbury serves as a Managing Member of BioBrit, LLC. is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. He served as the President of Amylin Pharmaceuticals, LLC (alternate name, Amylin Pharmaceuticals Inc.) from June 2006 to March 2007 and also served ... as its Chief Executive Officer from March 1, 2007 to August 2012, Chief Operating Officer from June 2003 to June 2006, Executive Vice President from June 2000 to June 2003, Senior Vice President of Corporate Development from April 1998 to June 2000, and Vice President of Marketing from June 1995 to April 1998. From July 1994 to May 1995, he served as Director of Marketing at Amylin Europe Limited. Prior to Amylin, Mr. Bradbury was employed at SmithKline Beecham Pharmaceuticals from September 1984 to July 1994, where he held a number of positions in international sales and marketing. He served at SmithKline Beecham Limited. He has been the Chairman of Liquid Grids, Inc. since May 13, 2014 and Freedom Meditech, Inc. since September 2014. He serves as the Chairman of Advisory Council at the Keck Graduate Institute of Applied Life Sciences. He serves as a Director of Syngene International Ltd. He has been a Director at Renova Therapeutics since November 2014. He has been an Independent Director of Geron Corporation since September 26, 2012. He has been a Director of BioMed Realty Trust Inc., since January 4, 2013. He serves as a Director of Cerexa, Inc, DiaVacs, Inc., Sensulin, Inc., Microdermis, Inc., BIOCOM, Inc., Castle Biosciences Incorporated, and Pharmaceutical Research and manufacturers of America (PhRMA). He has been a Director of Illumina Inc. since January 9, 2004 and Peninsula Pharmaceuticals Inc. since December 2003. He has been an Independent Director of Corcept Therapeutics Incorporated since October 15, 2012. He has been an Additional Director of Biocon Limited since April 25, 2013. He has been a Director of Profil Institute for Clinical Research, Inc. since November 2013. He serves as a Member of Advisory Board at MD Revolution Inc. He serves as a Member of Advisory Board of Investor Growth Capital and is responsible for biotechnology and pharmaceutical development. He has been Chairman of The Board at Castle Biosciences Incorporated since February 2015. He served as an Independent Director of Novacea, Inc. since September 2005 and its Lead Director since December 2007. Mr. Bradbury served as a Director of Amylin Pharmaceuticals, LLC from June 2006 to August 2012. He serves as a Member of Business Advisory Board at AmideBio, LLC. He serves as a Member of Advisory Council at The Rady School of Management at the University of California, San Diego. He is a Member of RAND Health Board of Advisors and University of Miami's Innovation Corporate Advisory Council. He has been honored with the San Diego American Diabetes Association's Father of the Year Award (2011), the Corporate Directors Forum Director of the Year Award for Enhancing Economic Value (2012) and was Ernst & Young's Entrepreneur of the Year Finalist (2012). Mr. Bradbury completed the Director Certification Program at the University of California, Los Angeles (2004) and the International Executive Program from INSEAD, European Institute of Business Administration, France (1994). He holds a B. Pharm (Hons.) from Nottingham University, UK in 1983 and a Postgraduate Diploma in Management Studies (DMS) and Diploma of the Chartered Institute of Marketing (DCIM) from Harrow and Ealing Colleges of Higher Education, UK (1985).

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.